File Download
  Links for fulltext
     (May Require Subscription)

Article: Broad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19)

TitleBroad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19)
Authors
Keywordscoronavirus
COVID-19
interferon
AM580
25-hydroxycholesterol
Issue Date2020
PublisherMolecular Diversity Preservation International (MDPI) AG.. The Journal's web site is located at http://www.mdpi.com/journal/viruses
Citation
Viruses, 2020, v. 12 n. 6, p. article no. 628 How to Cite?
AbstractThe ongoing Coronavirus Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) signals an urgent need for an expansion in treatment options. In this study, we investigated the anti-SARS-CoV-2 activities of 22 antiviral agents with known broad-spectrum antiviral activities against coronaviruses and/or other viruses. They were first evaluated in our primary screening in VeroE6 cells and then the most potent anti-SARS-CoV-2 antiviral agents were further evaluated using viral antigen expression, viral load reduction, and plaque reduction assays. In addition to remdesivir, lopinavir, and chloroquine, our primary screening additionally identified types I and II recombinant interferons, 25-hydroxycholesterol, and AM580 as the most potent anti-SARS-CoV-2 agents among the 22 antiviral agents. Betaferon (interferon-β1b) exhibited the most potent anti-SARS-CoV-2 activity in viral antigen expression, viral load reduction, and plaque reduction assays among the recombinant interferons. The lipogenesis modulators 25-hydroxycholesterol and AM580 exhibited EC50 at low micromolar levels and selectivity indices of >10.0. Combinational use of these host-based antiviral agents with virus-based antivirals to target different processes of the SARS-CoV-2 replication cycle should be evaluated in animal models and/or clinical trials.
Persistent Identifierhttp://hdl.handle.net/10722/285232
ISSN
2018 Impact Factor: 3.811
2015 SCImago Journal Rankings: 1.873
PubMed Central ID

 

DC FieldValueLanguage
dc.contributor.authorYuan, S-
dc.contributor.authorChan, CCY-
dc.contributor.authorChik, KKH-
dc.contributor.authorTsang, JOL-
dc.contributor.authorLiang, R-
dc.contributor.authorCao, J-
dc.contributor.authorTang, K-
dc.contributor.authorCai, JP-
dc.contributor.authorYe, ZW-
dc.contributor.authorYin, F-
dc.contributor.authorTo, KKW-
dc.contributor.authorChu, H-
dc.contributor.authorJin, DY-
dc.contributor.authorHung, IFN-
dc.contributor.authorYuen, KY-
dc.contributor.authorChan, JFW-
dc.date.accessioned2020-08-18T03:51:30Z-
dc.date.available2020-08-18T03:51:30Z-
dc.date.issued2020-
dc.identifier.citationViruses, 2020, v. 12 n. 6, p. article no. 628-
dc.identifier.issn1999-4915-
dc.identifier.urihttp://hdl.handle.net/10722/285232-
dc.description.abstractThe ongoing Coronavirus Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) signals an urgent need for an expansion in treatment options. In this study, we investigated the anti-SARS-CoV-2 activities of 22 antiviral agents with known broad-spectrum antiviral activities against coronaviruses and/or other viruses. They were first evaluated in our primary screening in VeroE6 cells and then the most potent anti-SARS-CoV-2 antiviral agents were further evaluated using viral antigen expression, viral load reduction, and plaque reduction assays. In addition to remdesivir, lopinavir, and chloroquine, our primary screening additionally identified types I and II recombinant interferons, 25-hydroxycholesterol, and AM580 as the most potent anti-SARS-CoV-2 agents among the 22 antiviral agents. Betaferon (interferon-β1b) exhibited the most potent anti-SARS-CoV-2 activity in viral antigen expression, viral load reduction, and plaque reduction assays among the recombinant interferons. The lipogenesis modulators 25-hydroxycholesterol and AM580 exhibited EC50 at low micromolar levels and selectivity indices of >10.0. Combinational use of these host-based antiviral agents with virus-based antivirals to target different processes of the SARS-CoV-2 replication cycle should be evaluated in animal models and/or clinical trials.-
dc.languageeng-
dc.publisherMolecular Diversity Preservation International (MDPI) AG.. The Journal's web site is located at http://www.mdpi.com/journal/viruses-
dc.relation.ispartofViruses-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectcoronavirus-
dc.subjectCOVID-19-
dc.subjectinterferon-
dc.subjectAM580-
dc.subject25-hydroxycholesterol-
dc.titleBroad-Spectrum Host-Based Antivirals Targeting the Interferon and Lipogenesis Pathways as Potential Treatment Options for the Pandemic Coronavirus Disease 2019 (COVID-19)-
dc.typeArticle-
dc.identifier.emailYuan, S: yuansf@hku.hk-
dc.identifier.emailLiang, R: liangrh@hku.hk-
dc.identifier.emailTang, K: kmtang20@hku.hk-
dc.identifier.emailCai, JP: caijuice@hku.hk-
dc.identifier.emailYe, ZW: zwye@hku.hk-
dc.identifier.emailTo, KKW: kelvinto@hku.hk-
dc.identifier.emailChu, H: hinchu@hku.hk-
dc.identifier.emailJin, DY: dyjin@hku.hk-
dc.identifier.emailHung, IFN: ivanhung@hkucc.hku.hk-
dc.identifier.emailYuen, KY: kyyuen@hkucc.hku.hk-
dc.identifier.emailChan, JFW: jfwchan@hku.hk-
dc.identifier.authorityYuan, S=rp02640-
dc.identifier.authorityTo, KKW=rp01384-
dc.identifier.authorityChu, H=rp02125-
dc.identifier.authorityJin, DY=rp00452-
dc.identifier.authorityHung, IFN=rp00508-
dc.identifier.authorityYuen, KY=rp00366-
dc.identifier.authorityChan, JFW=rp01736-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.3390/v12060628-
dc.identifier.pmid32532085-
dc.identifier.pmcidPMC7354423-
dc.identifier.scopuseid_2-s2.0-85086605233-
dc.identifier.hkuros312812-
dc.identifier.volume12-
dc.identifier.issue6-
dc.identifier.spagearticle no. 628-
dc.identifier.epagearticle no. 628-
dc.publisher.placeSwitzerland-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats